AUSTIN, TX and DURHAM, NC — August 21, 2025 — Leads & Copy — Shattuck Labs, Inc. (Shattuck), a biotechnology firm (NASDAQ: STTK), announced its Investigational New Drug (IND) application for SL-325, aimed at treating inflammatory bowel disease (IBD), has been approved by the FDA.
SL-325, a DR3 blocking antibody, has shown high-affinity binding to DR3 and potent inhibition of TL1A binding to DR3 in preclinical studies. A Phase 1 clinical trial, expected to dose its first participant in Q3 2025, will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. Enrollment is anticipated to conclude in Q2 2026.
Shattuck Labs anticipates current cash reserves, boosted by potential proceeds of up to $103 million from a recent private placement, will fund operations into 2029.
Taylor Schreiber, M.D., Ph.D., CEO of Shattuck, noted the IND approval as a significant advancement for SL-325, marking the beginning of clinical data collection for the DR3 blocking antibody.
Conor Richardson, Vice President of Investor Relations at Shattuck Labs, Inc., can be reached at InvestorRelations@shattucklabs.com.
Source: Shattuck Labs, Inc.
